FGF21 derivatives or FGF21 receptor agonists have been tried as therapeutic agents for various metabolic diseases, including type 2 diabetes, obesity, and NAFLD, for the past decade 21. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.